Abner Herrman & Brock LLC lifted its stake in shares of Abbott Laboratories (NYSE:ABT) by 2.4% during the fourth quarter, HoldingsChannel reports. The firm owned 206,342 shares of the healthcare product maker’s stock after buying an additional 4,793 shares during the period. Abbott Laboratories accounts for approximately 2.0% of Abner Herrman & Brock LLC’s holdings, making the stock its 18th largest position. Abner Herrman & Brock LLC’s holdings in Abbott Laboratories were worth $11,776,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Lee Financial Co increased its position in shares of Abbott Laboratories by 1.7% during the second quarter. Lee Financial Co now owns 3,388 shares of the healthcare product maker’s stock worth $165,000 after acquiring an additional 57 shares in the last quarter. Birmingham Capital Management Co. Inc. AL increased its position in shares of Abbott Laboratories by 1.8% during the second quarter. Birmingham Capital Management Co. Inc. AL now owns 33,894 shares of the healthcare product maker’s stock worth $1,648,000 after acquiring an additional 600 shares in the last quarter. Bessemer Group Inc. increased its position in shares of Abbott Laboratories by 12.3% during the second quarter. Bessemer Group Inc. now owns 55,874 shares of the healthcare product maker’s stock worth $2,716,000 after acquiring an additional 6,131 shares in the last quarter. Stewart & Patten Co. LLC increased its position in shares of Abbott Laboratories by 1.8% during the second quarter. Stewart & Patten Co. LLC now owns 306,771 shares of the healthcare product maker’s stock worth $14,913,000 after acquiring an additional 5,571 shares in the last quarter. Finally, Grove Bank & Trust increased its position in shares of Abbott Laboratories by 40.4% during the second quarter. Grove Bank & Trust now owns 20,442 shares of the healthcare product maker’s stock worth $993,000 after acquiring an additional 5,882 shares in the last quarter. Institutional investors own 71.22% of the company’s stock.

Shares of Abbott Laboratories (ABT) opened at $58.67 on Thursday. The company has a market cap of $102,120.00, a price-to-earnings ratio of 293.35, a price-to-earnings-growth ratio of 1.78 and a beta of 1.55. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.69 and a quick ratio of 2.26. Abbott Laboratories has a 12 month low of $42.28 and a 12 month high of $64.60.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Wednesday, January 24th. The healthcare product maker reported $0.74 EPS for the quarter, beating analysts’ consensus estimates of $0.73 by $0.01. The firm had revenue of $7.59 billion during the quarter, compared to analysts’ expectations of $7.38 billion. Abbott Laboratories had a net margin of 1.74% and a return on equity of 13.80%. The company’s revenue for the quarter was up 42.3% compared to the same quarter last year. During the same quarter last year, the company posted $0.65 earnings per share. equities research analysts expect that Abbott Laboratories will post 2.86 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, February 15th. Shareholders of record on Friday, January 12th will be paid a $0.28 dividend. The ex-dividend date is Thursday, January 11th. This represents a $1.12 dividend on an annualized basis and a yield of 1.91%. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.27. Abbott Laboratories’s dividend payout ratio (DPR) is currently 560.00%.

Several brokerages have recently issued reports on ABT. BMO Capital Markets reissued a “market perform” rating on shares of Abbott Laboratories in a research report on Thursday, October 19th. Wells Fargo & Co increased their price objective on shares of Abbott Laboratories from $66.00 to $70.00 and gave the stock an “outperform” rating in a research report on Thursday, January 25th. Leerink Swann reissued a “market perform” rating on shares of Abbott Laboratories in a research report on Friday, January 19th. Bank of America increased their price objective on shares of Abbott Laboratories from $60.00 to $70.00 in a research report on Wednesday, January 24th. They noted that the move was a valuation call. Finally, Royal Bank of Canada reissued a “buy” rating and set a $67.00 price objective on shares of Abbott Laboratories in a research report on Thursday, January 25th. Eight equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $65.47.

In other news, insider Alejandro D. Wellisch sold 2,153 shares of the firm’s stock in a transaction dated Wednesday, November 22nd. The shares were sold at an average price of $55.86, for a total transaction of $120,266.58. Following the completion of the sale, the insider now owns 10,256 shares in the company, valued at approximately $572,900.16. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Stephen R. Fussell sold 13,313 shares of the firm’s stock in a transaction dated Tuesday, January 30th. The stock was sold at an average price of $62.84, for a total transaction of $836,588.92. Following the sale, the executive vice president now owns 152,343 shares of the company’s stock, valued at approximately $9,573,234.12. The disclosure for this sale can be found here. In the last quarter, insiders sold 445,615 shares of company stock valued at $24,666,341. Corporate insiders own 0.76% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Abner Herrman & Brock LLC Increases Stake in Abbott Laboratories (ABT)” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://www.watchlistnews.com/abner-herrman-brock-llc-increases-stake-in-abbott-laboratories-abt/1851504.html.

Abbott Laboratories Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.